Teva And Polpharma Biologics Ink Global Licensing Deal For Ocrevus Biosimilar

Teva (via Teva Pharmaceuticals International) and Polpharma Biologics announced a global licensing agreement granting Teva exclusive commercialization rights for both formulations of Polpharma B. No financial terms or timeline details were provided in the excerpt, so near-term impact appears limited while the deal could be strategically positive if it expands Teva’s product revenue.

Analysis

Teva (via Teva Pharmaceuticals International) and Polpharma Biologics announced a global licensing agreement granting Teva exclusive commercialization rights for both formulations of Polpharma B. No financial terms or timeline details were provided in the excerpt, so near-term impact appears limited while the deal could be strategically positive if it expands Teva’s product revenue.